Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-6511
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat ; volume:14 ; number:1 ; day:29 ; month:8 ; year:2013 ; pages:1-3 ; date:8.2013
BMC pharmacology & toxicology ; 14, Heft 1 (29.8.2013), 1-3, 8.2013
- Urheber
-
Frey, Reiner
- Beteiligte Personen und Organisationen
-
Lettieri, John
Nadel, Andrea
Becker, Corina
Mück, Wolfgang
SpringerLink (Online service)
- DOI
-
10.1186/2050-6511-14-S1-P23
- URN
-
urn:nbn:de:1111-2016073154704
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Frey, Reiner
- Lettieri, John
- Nadel, Andrea
- Becker, Corina
- Mück, Wolfgang
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Structural studies of soluble guanylate cyclase
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Molecular steps in soluble guanylate cyclase activation
Lessons from soluble guanylate cyclase alpha1 knockouts
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis
The role of soluble guanylate cyclase in metabolism
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Structural studies of soluble guanylate cyclase
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Molecular steps in soluble guanylate cyclase activation
Lessons from soluble guanylate cyclase alpha1 knockouts
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis
The role of soluble guanylate cyclase in metabolism
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Structural studies of soluble guanylate cyclase
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Molecular steps in soluble guanylate cyclase activation
Lessons from soluble guanylate cyclase alpha1 knockouts
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis